China Traditional Chinese Medicine Holdings Limited ("Trad Chi Med") issued a profit warning on August 21, 2024, expecting a year-on-year decline of 60%-70% in net profit for the six months ending June 30, 2024. The reasons for the decline include the decrease in profitability of the traditional Chinese medicine granule business due to lower procurement prices and intensified market competition, the increase in accounts receivable leading to increased credit impairment losses, and the impact of tax payments by certain subsidiary companies on net profit. In addition, the company mentioned the privatization proposal with China National Pharmaceutical Group Co., Ltd. and stated that the offering period of the proposal started on February 21, 2024. The Board of Directors is responsible for the accuracy of the announcement and confirms that the announcement has been carefully considered with no misleading content.

China Traditional Chinese Medicine Holdings Limited ("Trad Chi Med") issued a profit warning on August 21, 2024, expecting a year-on-year decline of 60%-70% in net profit for the six months ending June 30, 2024. The reasons for the decline include the decrease in profitability of the traditional Chinese medicine granule business due to lower procurement prices and intensified market competition, the increase in accounts receivable leading to increased credit impairment losses, and the impact of tax payments by certain subsidiary companies on net profit. In addition, the company mentioned the privatization proposal with China National Pharmaceutical Group Co., Ltd. and stated that the offering period of the proposal started on February 21, 2024. The Board of Directors is responsible for the accuracy of the announcement and confirms that the announcement has been carefully considered with no misleading content.